[go: up one dir, main page]

WO2006104852A3 - Vegf antagonist formulations - Google Patents

Vegf antagonist formulations Download PDF

Info

Publication number
WO2006104852A3
WO2006104852A3 PCT/US2006/010600 US2006010600W WO2006104852A3 WO 2006104852 A3 WO2006104852 A3 WO 2006104852A3 US 2006010600 W US2006010600 W US 2006010600W WO 2006104852 A3 WO2006104852 A3 WO 2006104852A3
Authority
WO
WIPO (PCT)
Prior art keywords
vegf antagonist
antagonist formulations
formulations
fusion protein
lyophilized formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2006/010600
Other languages
French (fr)
Other versions
WO2006104852A2 (en
Inventor
Daniel Dix
Kelly Frye
Susan Kautz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36678320&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2006104852(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to PL06748594T priority Critical patent/PL1861116T3/en
Priority to JP2008503191A priority patent/JP5376573B2/en
Priority to NZ560713A priority patent/NZ560713A/en
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Priority to KR1020077024202A priority patent/KR101327270B1/en
Priority to DK06748594.6T priority patent/DK1861116T3/en
Priority to ES06748594.6T priority patent/ES2548238T3/en
Priority to HK08105425.6A priority patent/HK1116050B/en
Priority to AU2006229930A priority patent/AU2006229930C1/en
Priority to CN2006800085696A priority patent/CN101141975B/en
Priority to CA2598711A priority patent/CA2598711C/en
Priority to SI200631996T priority patent/SI1861116T1/en
Priority to EP06748594.6A priority patent/EP1861116B1/en
Publication of WO2006104852A2 publication Critical patent/WO2006104852A2/en
Publication of WO2006104852A3 publication Critical patent/WO2006104852A3/en
Priority to IL185606A priority patent/IL185606A/en
Anticipated expiration legal-status Critical
Priority to IL227215A priority patent/IL227215A/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7012—Compounds having a free or esterified carboxyl group attached, directly or through a carbon chain, to a carbon atom of the saccharide radical, e.g. glucuronic acid, neuraminic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C07K2318/20—Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Formulations of a vascular endothelial growth factor (VEGF)-specific fusion protein antagonist are provided including a pre-lyophilized formulation, a reconstituted lyophilized formulation, and a stable liquid formulation. Preferably, the fusion protein has the sequence of SEQ ID NO:4.
PCT/US2006/010600 2005-03-25 2006-03-22 Vegf antagonist formulations Ceased WO2006104852A2 (en)

Priority Applications (14)

Application Number Priority Date Filing Date Title
EP06748594.6A EP1861116B1 (en) 2005-03-25 2006-03-22 Vegf antagonist formulations
AU2006229930A AU2006229930C1 (en) 2005-03-25 2006-03-22 VEGF antagonist formulations
NZ560713A NZ560713A (en) 2005-03-25 2006-03-22 VEGF antagonist formulations
CA2598711A CA2598711C (en) 2005-03-25 2006-03-22 Vegf antagonist formulations
KR1020077024202A KR101327270B1 (en) 2005-03-25 2006-03-22 Vegf antagonist formulation
DK06748594.6T DK1861116T3 (en) 2005-03-25 2006-03-22 VEGF antagonist formulations
ES06748594.6T ES2548238T3 (en) 2005-03-25 2006-03-22 VEGF antagonist formulations
HK08105425.6A HK1116050B (en) 2005-03-25 2006-03-22 Vegf antagonist formulations
CN2006800085696A CN101141975B (en) 2005-03-25 2006-03-22 Vegf antagonist formulations
PL06748594T PL1861116T3 (en) 2005-03-25 2006-03-22 Vegf antagonist formulations
JP2008503191A JP5376573B2 (en) 2005-03-25 2006-03-22 VEGF antagonist preparation
SI200631996T SI1861116T1 (en) 2005-03-25 2006-03-22 Vegf antagonist formulations
IL185606A IL185606A (en) 2005-03-25 2007-08-30 Vegf antagonist formulations and methods for producing the same
IL227215A IL227215A (en) 2005-03-25 2013-06-27 Vegf antagonist formulations

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US66512505P 2005-03-25 2005-03-25
US60/665,125 2005-03-25

Publications (2)

Publication Number Publication Date
WO2006104852A2 WO2006104852A2 (en) 2006-10-05
WO2006104852A3 true WO2006104852A3 (en) 2007-02-01

Family

ID=36678320

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/010600 Ceased WO2006104852A2 (en) 2005-03-25 2006-03-22 Vegf antagonist formulations

Country Status (19)

Country Link
US (16) US20060217311A1 (en)
EP (3) EP1861116B1 (en)
JP (2) JP5376573B2 (en)
KR (1) KR101327270B1 (en)
CN (2) CN102614134B (en)
AU (1) AU2006229930C1 (en)
CA (3) CA2995971A1 (en)
CY (2) CY1116980T1 (en)
DK (2) DK1861116T3 (en)
ES (2) ES2633574T3 (en)
HU (2) HUE027096T2 (en)
IL (2) IL185606A (en)
LT (1) LT2586459T (en)
NZ (1) NZ560713A (en)
PL (2) PL2586459T3 (en)
PT (2) PT1861116E (en)
SI (2) SI2586459T1 (en)
WO (1) WO2006104852A2 (en)
ZA (1) ZA200708845B (en)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7655758B2 (en) 2004-08-17 2010-02-02 Regeneron Pharmaceuticals, Inc. Stable liquid IL-1 antagonist formulations
US7572893B2 (en) * 2004-08-17 2009-08-11 Regeneron Pharmaceuticals, Inc. IL-1 antagonist formulations
ES2633574T3 (en) 2005-03-25 2017-09-22 Regeneron Pharmaceuticals, Inc. VEGF antagonist formulations
SI2944306T1 (en) 2006-06-16 2021-04-30 Regeneron Pharmaceuticals, Inc. Vegf antagonist formulations suitable for intravitreal administration
AU2012202859C1 (en) * 2006-06-16 2025-08-07 Regeneron Pharmaceuticals, Inc. VEGF antagonist formulations suitable for intravitreal administration
DK2222697T3 (en) 2007-11-01 2013-03-11 Perseid Therapeutics Llc Immunosuppressive polypeptides and nucleic acids
RU2550258C2 (en) * 2008-11-03 2015-05-10 Молекьюлар Партнерс Аг Binding proteins inhibiting vegf-a receptor interaction
KR101867279B1 (en) 2010-10-06 2018-06-15 리제너론 파아마슈티컬스, 인크. Stabilized formulations containing anti-interleukin-4 receptor(il-4r) antibodies
CN102552875B (en) * 2010-12-09 2015-05-20 上海国健生物技术研究院 Difunctional VEGFA acceptor fusion protein preparation
MX385629B (en) 2011-01-13 2025-03-18 Regeneron Pharma USE OF A VASCULAR ENDOTHELIAL GROWTH FACTOR ANTAGONIST TO TREAT ANGIOGENIC OCULAR DISORDERS.
JP6204906B2 (en) * 2011-04-14 2017-09-27 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Multilayer thin film drug delivery device and methods for making and using the same
JO3283B1 (en) 2011-04-26 2018-09-16 Sanofi Sa Composition including Afflipersept, Folinic Acid, 5- Fluorouracil (5- Fu) and Irenosetan (FOLFIRI)
ES2810003T3 (en) 2011-11-18 2021-03-08 Regeneron Pharma Microparticle containing therapeutic protein coated with biodegradable polymer for medical use
MY164611A (en) 2012-01-23 2018-01-30 Regeneron Pharma Stabilized formulations containing anti-ang2 antibodies
KR102213535B1 (en) * 2012-03-16 2021-02-08 리제너론 파마슈티칼스 인코포레이티드 Non-human animals expressing ph-sensitive immunoglobulin sequences
AR092325A1 (en) * 2012-05-31 2015-04-15 Regeneron Pharma STABILIZED FORMULATIONS CONTAINING ANTI-DLL4 ANTIBODIES AND KIT
WO2014006113A1 (en) 2012-07-03 2014-01-09 Sanofi Method of treating cancer by effective amounts of aflibercept
SG11201500480TA (en) * 2012-08-02 2015-02-27 Sanofi Sa Article of manufacture comprising aflibercept or ziv-aflibercept
UA115789C2 (en) 2012-09-05 2017-12-26 Трейкон Фармасутікалз, Інк. Antibody formulations and uses thereof
CN103110105A (en) * 2012-11-14 2013-05-22 江苏江山制药有限公司 Production method for food additive sugar-free vitamin C sodium salt particles
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
SI3170005T1 (en) 2014-07-18 2019-08-30 Sanofi Method for predicting the outcome of a treatment with aflibercept of a patient suspected to suffer from a cancer
CN104940926B (en) 2014-09-25 2017-09-22 信达生物制药(苏州)有限公司 Recombination fusion protein preparation
CN105435222B (en) 2014-09-25 2018-05-29 信达生物制药(苏州)有限公司 Recombination fusion protein preparation
WO2016080367A1 (en) * 2014-11-18 2016-05-26 塩野義製薬株式会社 Stable peptide composition
US10894083B2 (en) 2015-01-28 2021-01-19 Pfizer Inc. Stable aqueous anti-vascular endothelial growth factor (VEGF) antibody formulation
KR101808234B1 (en) * 2015-06-23 2017-12-12 (주)알테오젠 A stable liquid formulation of fusion protein with IgG Fc domain
CN114712497B (en) 2015-12-03 2024-03-22 雷杰纳荣制药公司 Use of anti-VEGF agents for the preparation of a medicament for the treatment of patients suffering from neovascular age-related macular degeneration
WO2017117464A1 (en) 2015-12-30 2017-07-06 Kodiak Sciences Inc. Antibodies and conjugates thereof
US10576128B2 (en) * 2016-01-26 2020-03-03 Formycon Ag Liquid formulation of a VEGF antagonist
KR101685532B1 (en) * 2016-04-26 2016-12-13 한국프라임제약주식회사 A VEGFR fusion protein
US11351256B2 (en) 2016-10-07 2022-06-07 Regeneron Pharmaceuticals, Inc. Room temperature stable lyophilized protein
WO2018094316A1 (en) 2016-11-21 2018-05-24 Just Biotherapeutics, Inc. Aflibercept formulations and uses thereof
USD849856S1 (en) 2017-06-28 2019-05-28 Jumpsport, Inc. Standing platform
TWI810196B (en) * 2017-07-25 2023-08-01 大陸商江蘇恆瑞醫藥股份有限公司 Il-15 protein complex pharmaceutical composition and use thereof
WO2019020777A1 (en) 2017-07-26 2019-01-31 Formycon Ag Liquid formulation of a vegf antagonist
MX2020005170A (en) 2017-11-17 2020-10-16 Amgen Inc Vegfr-fc fusion protein formulations.
JP7183268B2 (en) 2017-11-20 2022-12-05 ジャスト－エヴォテック バイオロジックス、インコーポレイテッド Aflibercept formulation containing lysine salt as tonicity agent and its use
HUE059827T2 (en) 2017-11-30 2023-01-28 Regeneron Pharma Use of a VEGF antagonist for the treatment of angiogenic eye diseases
CA3189025A1 (en) * 2017-12-22 2019-06-27 Samsung Bioepis Co., Ltd. Liquid composition comprising vegf antagonist
US11524053B2 (en) 2018-01-26 2022-12-13 The Regents Of The University Of California Methods and compositions for treatment of angiogenic disorders using anti-VEGF agents
BR112020017872A2 (en) 2018-03-02 2020-12-22 Kodiak Sciences Inc. IL-6 ANTIBODIES AND FUSION CONSTRUCTS AND CONJUGATES OF THE SAME
US11426446B2 (en) 2018-03-08 2022-08-30 Coherus Biosciences, Inc. Stable aqueous formulations of aflibercept
US11667702B2 (en) 2018-03-08 2023-06-06 Coherus Biosciences, Inc. Stable aqueous formulations of aflibercept
CN108671229B (en) * 2018-05-08 2022-03-25 华博生物医药技术（上海）有限公司 Pharmaceutical composition preparation of recombinant human vascular endothelial growth factor receptor-antibody fusion protein
NZ770284A (en) 2018-05-10 2025-11-28 Regeneron Pharma High concentration vegf receptor fusion protein containing formulations
US11519020B2 (en) 2018-05-25 2022-12-06 Regeneron Pharmaceuticals, Inc. Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF
WO2021050687A1 (en) 2019-09-10 2021-03-18 Coherus Biosciences, Inc. Stable aqueous formulations of aflibercept
WO2021072265A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
IL293131A (en) 2019-11-25 2022-07-01 Univ California Long-acting vegf inhibitors for intraocular neovascularization
JP2022548197A (en) 2019-12-06 2022-11-17 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ANTI-VEGF PROTEIN COMPOSITION AND METHOD FOR MANUFACTURE THEREOF
KR102337471B1 (en) * 2019-12-23 2021-12-09 한국프라임제약주식회사 A pharmaceutical formulation comprising VEGFR fusion protein
CN115803009A (en) 2020-05-08 2023-03-14 瑞泽恩制药公司 VEGF traps and microwells and methods for treating ocular diseases and cancer
CA3190325A1 (en) * 2020-07-31 2022-02-03 Celltrion Inc. Stable pharmaceutical preparation
WO2025140553A1 (en) * 2023-12-27 2025-07-03 成都康弘生物科技有限公司 Pharmaceutical composition containing anti-vegf fusion protein
US12240888B1 (en) 2024-04-29 2025-03-04 QILU Pharmaceutical, Co., Ltd. Composition comprising aflibercept and a variant thereof, and related methods and uses

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020004478A1 (en) * 1998-06-01 2002-01-10 Stephen Danko Pharmaceutical formulations for igf/igfbp
WO2005000895A2 (en) * 2003-06-30 2005-01-06 Regeneron Pharmaceuticals, Inc. Vegf traps and therapeutic uses thereof

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993000807A1 (en) 1991-07-03 1993-01-21 Cryolife, Inc. Method for stabilization of biomaterials
AU670793B2 (en) * 1992-04-30 1996-08-01 Alpha Therapeutic Corporation Improved solubilization and stabilization of factor VIII complex
US6177401B1 (en) * 1992-11-13 2001-01-23 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis
GB9410534D0 (en) * 1994-05-26 1994-07-13 Lynxvale Ltd Improvements in or relating to growth factor inhibitors
US6685940B2 (en) * 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
MX9800684A (en) * 1995-07-27 1998-04-30 Genentech Inc Stabile isotonic lyophilized protein formulation.
US6267958B1 (en) * 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
JPH09154588A (en) * 1995-10-07 1997-06-17 Toagosei Co Ltd Vegf-binding polypeptide
US6100071A (en) * 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
US5763401A (en) 1996-07-12 1998-06-09 Bayer Corporation Stabilized albumin-free recombinant factor VIII preparation having a low sugar content
US7312196B2 (en) * 1997-01-08 2007-12-25 Amylin Pharmaceuticals, Inc. Formulations for amylin agonist peptides
JPH10273450A (en) 1997-03-27 1998-10-13 Toagosei Co Ltd Therapeutic agent for intraocular neovascular disease
ES2236634T3 (en) 1997-04-07 2005-07-16 Genentech, Inc. ANTI-VEGF ANTIBODIES.
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
JPH1180024A (en) 1997-09-12 1999-03-23 Toagosei Co Ltd Corneal vascular rebirth inhibitor
US6472179B2 (en) * 1998-09-25 2002-10-29 Regeneron Pharmaceuticals, Inc. Receptor based antagonists and methods of making and using
EP1171594B1 (en) 1999-04-16 2006-06-07 Genentech, Inc. Vascular endothelial cell growth factor variants and uses thereof
CN1308347C (en) 1999-04-28 2007-04-04 德克萨斯大学董事会 Compositions and methods for treating cancer by selective inhibition of VEGF
US7396664B2 (en) * 1999-06-08 2008-07-08 Regeneron Pharmaceuticals, Inc. VEGF-binding fusion proteins and nucleic acids encoding the same
US6833349B2 (en) * 1999-06-08 2004-12-21 Regeneron Pharmaceuticals, Inc. Methods of treating inflammatory skin diseases
US7070959B1 (en) 1999-06-08 2006-07-04 Regeneron Pharmaceuticals, Inc. Modified chimeric polypeptides with improved pharmacokinetic properties
JP4723140B2 (en) 1999-06-08 2011-07-13 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Modified chimeric polypeptide with improved pharmacokinetic properties
US7001892B1 (en) * 1999-06-11 2006-02-21 Purdue Research Foundation Pharmaceutical materials and methods for their preparation and use
IL155002A0 (en) * 2000-10-12 2003-10-31 Genentech Inc Reduced-viscosity concentrated protein formulations
ATE454137T1 (en) * 2001-07-25 2010-01-15 Facet Biotech Corp STABLE LYOPHILIZED PHARMACEUTICAL FORMULATION OF THE IGG ANTIBODY DACLIZUMAB
US20030138417A1 (en) 2001-11-08 2003-07-24 Kaisheva Elizabet A. Stable liquid pharmaceutical formulation of IgG antibodies
US20030180287A1 (en) 2002-02-27 2003-09-25 Immunex Corporation Polypeptide formulation
DE602004004883T2 (en) * 2003-03-28 2007-11-15 Regeneron Pharmaceuticals, Inc. VEGF ANTAGONISTS FOR THE TREATMENT OF DIABETES
DK1610820T4 (en) * 2003-04-04 2013-11-04 Genentech Inc High-concentration antibody and protein formulations
WO2004103159A2 (en) * 2003-05-14 2004-12-02 The Board Of Trustees Of The Leland Stanford Junior University Methods for modulating endometrium
EP1626989A2 (en) 2003-05-28 2006-02-22 Regeneron Pharmaceuticals, Inc. Method of treating corneal transplant rejection by using vegf antagonists
US7354578B2 (en) 2003-06-06 2008-04-08 Regeneron Pharmaceuticals, Inc. Method of tumor regression with VEGF inhibitors
ITMI20031261A1 (en) 2003-06-20 2004-12-21 Messersi Packaging Srl STRAPPING MACHINE WITH PERFECTED STRAP HANDLING GROUP.
AR046510A1 (en) 2003-07-25 2005-12-14 Regeneron Pharma COMPOSITION OF A VEGF ANTAGONIST AND AN ANTI-PROLIFERATIVE AGENT
US20050112061A1 (en) 2003-08-06 2005-05-26 Jocelyn Holash Use of a VEGF antagonist in combination with radiation therapy
PL1660057T3 (en) 2003-08-27 2012-10-31 Ophthotech Corp Combination therapy for the treatment of ocular neovascular disorders
WO2005072772A1 (en) * 2004-01-30 2005-08-11 Suomen Punainen Risti Veripalvelu Pharmaceutical compositions
ATE507240T1 (en) 2004-03-05 2011-05-15 Vegenics Pty Ltd MATERIALS AND METHODS FOR GROWTH FACTOR BINDING CONSTRUCTS
EP1740168A2 (en) 2004-04-21 2007-01-10 Advanced Ocular Systems Limited Antiprostaglandins for the treatment of ocular pathologies
CN100361710C (en) 2004-06-07 2008-01-16 成都康弘生物科技有限公司 Construction and application of oncolytic adenovirus recombinant of tumor cell specifically expressing immunoregulation factor GM-CSF
DK1767546T3 (en) 2004-06-08 2012-04-23 Chengdu Kanghong Biotechnologies Co Ltd Angiogenesis-inhibiting chimeric protein and its use
CN1304427C (en) 2004-06-08 2007-03-14 成都康弘生物科技有限公司 Angiogenesis inhibiting fusion protein and its use
EP2583685A1 (en) 2004-06-10 2013-04-24 Regeneron Pharmaceuticals, Inc. Method of administering and using VEGF inhibitors for the treatment of human cancer
EP1755645A2 (en) 2004-06-18 2007-02-28 Regeneron Pharmaceuticals, Inc. Vegf inhibitors for the treatment of malignant pleural effusion
AU2005267741A1 (en) 2004-07-30 2006-02-09 Regeneron Pharmaceuticals, Inc. Methods of treating type I diabetes by blocking VEGF-mediated activity
EP2311433A3 (en) 2004-10-21 2011-08-10 Genentech, Inc. Method for treating intraocular neovascular diseases
CA2621047A1 (en) 2005-02-02 2006-08-24 Regeneron Pharmaceuticals, Inc. Method of treating eye injury with local administration of a vegf inhibitor
ES2633574T3 (en) 2005-03-25 2017-09-22 Regeneron Pharmaceuticals, Inc. VEGF antagonist formulations
EP1909831A4 (en) 2005-06-14 2013-02-20 Amgen Inc PREPARATIONS OF SPONTANEOUS TAMPING PROTEINS
CN100502945C (en) 2006-03-31 2009-06-24 成都康弘生物科技有限公司 Use of VEGF receptor fusion proteins for treating ocular diseases
US8216575B2 (en) 2006-03-31 2012-07-10 Chengdu Kanghong Biotechnologies Co., Ltd. Inhibition of neovascularization with a soluble chimeric protein comprising VEGF FLT-1 and KDR domains
CN100567325C (en) 2006-03-31 2009-12-09 成都康弘生物科技有限公司 VEGF receptor fusion protein and its application in the preparation of medicines for treating eye diseases
SI2944306T1 (en) 2006-06-16 2021-04-30 Regeneron Pharmaceuticals, Inc. Vegf antagonist formulations suitable for intravitreal administration
CN102233132B (en) 2010-04-28 2013-10-23 成都康弘生物科技有限公司 Application of VEGF acceptor fusion proteins in preparation of drugs for inhibiting growth of ocular surface neovascularization
CN102380096B (en) 2010-08-31 2014-04-30 成都康弘生物科技有限公司 A pharmaceutical composition containing a fusion protein for inhibiting angiogenesis and its application
CN103212075B (en) 2012-01-19 2017-06-27 成都康弘生物科技有限公司 A kind of eye drops containing VEGF antagonist
JOP20200175A1 (en) 2012-07-03 2017-06-16 Novartis Ag Syringe
RU2634406C1 (en) 2014-01-25 2017-10-26 Чэнду Канхун Байотекнолоджиз Ко., Лтд. Fused protein, inhibiting angiogenesis or growth of vessels, and its application
US20160144025A1 (en) 2014-11-25 2016-05-26 Regeneron Pharmaceuticals, Inc. Methods and formulations for treating vascular eye diseases

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020004478A1 (en) * 1998-06-01 2002-01-10 Stephen Danko Pharmaceutical formulations for igf/igfbp
WO2005000895A2 (en) * 2003-06-30 2005-01-06 Regeneron Pharmaceuticals, Inc. Vegf traps and therapeutic uses thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
GLADE-BENDER J ET AL: "VEGF BLOCKING THERAPY IN THE TREATMENT OF CANCER", EXPERT OPINION ON BIOLOGICAL THERAPY, ASHLEY, LONDON, GB, vol. 3, no. 2, April 2003 (2003-04-01), pages 263 - 276, XP009060849, ISSN: 1471-2598 *
HOLASH JOCELYN ET AL: "VEGF-Trap: A VEGF blocker with potent antitumor effects", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 99, no. 17, 20 August 2002 (2002-08-20), pages 11393 - 11398, XP002391854, ISSN: 0027-8424 *
KIM EUGENE S ET AL: "Potent VEGF blockade causes regression of coopted vessels in a model of neuroblastoma", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 99, no. 17, 20 August 2002 (2002-08-20), pages 11399 - 11404, XP002391853, ISSN: 0027-8424 *

Also Published As

Publication number Publication date
US20210393778A1 (en) 2021-12-23
ES2548238T3 (en) 2015-10-15
PT2586459T (en) 2017-07-25
US20190388539A1 (en) 2019-12-26
HUE034109T2 (en) 2018-01-29
KR101327270B1 (en) 2013-11-08
IL227215A (en) 2016-02-29
AU2006229930A1 (en) 2006-10-05
ZA200708845B (en) 2010-07-28
US20160244504A1 (en) 2016-08-25
US10406226B2 (en) 2019-09-10
CY1119243T1 (en) 2018-02-14
US20210393530A1 (en) 2021-12-23
US20150079087A1 (en) 2015-03-19
EP3195874A1 (en) 2017-07-26
US9416167B2 (en) 2016-08-16
US20130261056A1 (en) 2013-10-03
WO2006104852A2 (en) 2006-10-05
US20120101035A1 (en) 2012-04-26
US20160175439A1 (en) 2016-06-23
US20120178683A1 (en) 2012-07-12
CA2598711A1 (en) 2006-10-05
EP1861116A2 (en) 2007-12-05
CN101141975A (en) 2008-03-12
JP2013079270A (en) 2013-05-02
US11806398B2 (en) 2023-11-07
JP2008535819A (en) 2008-09-04
NZ560713A (en) 2010-11-26
US9636400B2 (en) 2017-05-02
US20210252147A1 (en) 2021-08-19
EP2586459A1 (en) 2013-05-01
US8921316B2 (en) 2014-12-30
PL1861116T3 (en) 2016-02-29
DK1861116T3 (en) 2015-11-09
IL185606A0 (en) 2008-01-06
CN101141975B (en) 2012-05-23
US20170360930A1 (en) 2017-12-21
HK1116050A1 (en) 2008-12-19
CA2598711C (en) 2018-05-29
SI1861116T1 (en) 2015-12-31
KR20080015780A (en) 2008-02-20
CN102614134B (en) 2016-09-07
US8110546B2 (en) 2012-02-07
US8404638B2 (en) 2013-03-26
HUE027096T2 (en) 2016-08-29
LT2586459T (en) 2017-09-25
US8710004B2 (en) 2014-04-29
CA3142945A1 (en) 2006-10-05
ES2633574T3 (en) 2017-09-22
US20210077624A1 (en) 2021-03-18
CN102614134A (en) 2012-08-01
DK2586459T3 (en) 2017-09-11
US20170073407A1 (en) 2017-03-16
US20100279933A1 (en) 2010-11-04
CA2995971A1 (en) 2006-10-05
SI2586459T1 (en) 2017-10-30
AU2006229930B2 (en) 2010-08-05
EP1861116B1 (en) 2015-09-16
JP5376573B2 (en) 2013-12-25
AU2006229930C1 (en) 2013-07-25
PT1861116E (en) 2015-11-04
US10857231B2 (en) 2020-12-08
US20210252105A1 (en) 2021-08-19
US9511140B2 (en) 2016-12-06
CY1116980T1 (en) 2017-04-05
IL185606A (en) 2013-08-29
JP5752671B2 (en) 2015-07-22
PL2586459T3 (en) 2017-12-29
US20060217311A1 (en) 2006-09-28
EP2586459B1 (en) 2017-05-24

Similar Documents

Publication Publication Date Title
WO2006104852A3 (en) Vegf antagonist formulations
WO2007149334A3 (en) Vegf antagonist formulations suitable for intravitreal administration
MX2007002189A (en) Diketopiperazine salts, diketomorpholine salts or diketodioxane salts for drug delivery.
WO2008073448A3 (en) Pharmaceutical formulations and methods for making the same
WO2010019266A3 (en) Linaclotide-containing formulations for oral administration
WO2006023665A3 (en) Il-1 antagonist formulations
WO2005097202A3 (en) Use of serum albumin binding peptides conjugates for the preparation of a medicament
WO2005112633A3 (en) Compounds and compositions for delivering active agents
WO2002043736A1 (en) Beautifying foods and drinks and peroral beautifying preparations
WO2006010057A3 (en) Therapeutic peptides
WO2007015252A3 (en) Somatic cells for use in cell therapy
NZ601592A (en) Recombinant elastase proteins and methods of manufacturing and use thereof
WO2007025988A3 (en) Liquid formulations of pegylated growth hormone
WO2003089458A3 (en) Conjugates of membrane translocating agents and pharmaceutically active agents
WO2004062555A3 (en) Use of natriuretic peptides for the treatment of stature disorders related to the shox gene
WO2002015959A3 (en) Compounds and compositions for delivering active agents
WO2006065722A3 (en) Compositions and methods for pulmonary conditions
WO2007109648A8 (en) Compositions and methods for modulating store-operated calcium entry
WO2005108428A3 (en) Cd40 splice variants and their uses
WO2001005811A3 (en) Cyclic peptidomimetic urokinase receptor antagonists
EP2371379A3 (en) New formulation for increasing bioavailability of neurturin
WO2000070665A3 (en) Long lasting anti-angiogenic peptides
WO2007081419A3 (en) Compositions and methods related to anti-fgf agents
WO2006109303A3 (en) Chimeric proteins comprising yersinia yop, their preparation and pharmaceutical compositions containing them
WO2006047728A3 (en) Bmp gene and fusion protein

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200680008569.6

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 560713

Country of ref document: NZ

Ref document number: 2006229930

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2598711

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 185606

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 6802/DELNP/2007

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 2006229930

Country of ref document: AU

Date of ref document: 20060322

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2006748594

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2008503191

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 1020077024202

Country of ref document: KR

NENP Non-entry into the national phase

Ref country code: RU